Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831 (NEUROSIVIR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04480333
Recruitment Status : Recruiting
First Posted : July 21, 2020
Last Update Posted : July 21, 2020
Sponsor:
Information provided by (Responsible Party):
NeuroActiva, Inc.

Brief Summary:
The clinical study is designed to evaluate the safety, tolerability and pharmacokinetics of inhaled nanoparticle nanoparticle formulation of Remdesivir (GS-5734) alone and in combination with NA-831 in 48 healthy volunteers.

Condition or disease Intervention/treatment Phase
Covid19 Corona Virus Infection Severe Acute Respiratory Syndrome Severe Acute Respiratory Infection Severe Acute Respiratory Syndrome (SARS) Pneumonia Severe Acute Respiratory Syndrome of Upper Respiratory Tract Neurodegeneration Neuroinflammatory Response Drug: Drug: NA-831 - 0.10 mg/kg Drug: Placebo- 0.10 mg/kg Drug: Drug: NA-831 - 0.20 mg/kg Drug: Placebo- 0.20 mg/kg Drug: Drug: GS-5734 - 1.00 mg/kg Drug: Placebo- 1.00 mg/kg Drug: Drug: GS-5734 - 2.00 mg/kg Drug: Placebo- 2.00 mg/kg Combination Product: Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) Combination Product: Placebo 0.10 mg + 1.00 mg/kg Combination Product: Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg) Combination Product: Placebo 0.20 mg + 2.00 mg/kg Phase 1

Detailed Description:

It has been discovered that SARS-CoV-2 viruses (Covid-19) can directly invade the nervous system of patients, instead of injuring the nervous system through the immune response. Neurotropism is one common feature of Covid-19. Such neuro-invasive propensity of Covid-19 has been documented almost for all the Beta-coronaviruses including SARS-CoV and MERS-CoV.

Increasing evidence suggests that infection with Sars-CoV-2 causes neurological deficits in a substantial proportion of affected patients. It was observed that patients surviving COVID-19 are at high risk for subsequent development of neurological disease and in particular Alzheimer's disease.

NA-831 is a new neuroprotective and neurogenesis drug that has been demonstrated its promising safety and efficacy in Phase 2A for the treatment of early onset of Alzheimer's disease. NA-831 in oral formulation is well tolerated NA-831 with no adverse effects. NA-831 in oral formulation exhibits predictable pharmacokinetics including dose-dependent exposure linearity and low variability.

Based on animal studies, NA-831 can provide effective interventions during the severe acute respiratory syndrome, and provide appropriate rehabilitation measures afterwards.

Remdesivir (GS-5734) intravenous formulation has been approved by the FDA under the emergency use authorization for potential treatment of severe cases of Covid-19.

It was found the upper respiratory tract is the most prevalent site of SARS-CoV-2 infection early in disease. Delivering drugs directly to the primary site of infection with a nebulizer, inhaled nanoparticle formulation may enable more targeted and accessible administration in non-hospitalized patients and potentially lower systemic exposure to the drug.

The study is designed to evaluate the safety, tolerability and pharmacokinetics of a new nanoparticle formulation of Remdesivir (GS-5734) and combination therapy with NA-831 in healthy volunteers.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:

The dose escalation given to healthy volunteers across the following cohorts:

NA-831 cohorts:

0.1 mg/kg NA-831, number of subjects N=2 and 2 subjects on placebos 0.2 mg/kg NA-831, number of subjects N=4 and 2 subjects on placebos 0.5 mg/kg NA-831, number of subjects N=4 and 2 subjects on placebos

GS-5734 cohorts:

  1. mg/kg GS-5734, number of subjects N=2 and 2 subjects on placebos
  2. mg/kg GS-5734, number of subjects N=4 and 2 subjects on placebos

4 mg/kg GS-5734, number of subjects N=4 and 2 subjects on placebos

NA-831 plus GS-5734 cohorts:

0.1 mg/kg NA-831 plus 1 mg/kg GS-5734, number of subjects N=2 and 2 subjects on placebos 0.2 mg/kg NA-831 plus 2 mg/kg GS-5734, number of subjects N=4 and 2 subjects on placebos 0.5 mg/kg NA-831 plus 4 mg/kg GS-5734, number of subjects N=4 and 2 subjects on placebos.

Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and in Combination With NA-831 in Healthy Volunteers
Estimated Study Start Date : September 15, 2020
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : March 31, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Drug: NA-831 - 0.10 mg/kg
3 Subjects will take inhaled formulation of NA-831 once a day for 5 days
Drug: Drug: NA-831 - 0.10 mg/kg
NA-831 in nanoparticle inhalation formulation
Other Name: NA-831 is a neuroprotective and neurogenesis drug

Placebo Comparator: Comparable Placebo- 0.10 mg/kg
3 subjects will take inhaled formulation of placebo once a day for 5 days
Drug: Placebo- 0.10 mg/kg
Placebo in nanoparticle inhalation formulation
Other Name: Placebo Comparator

Experimental: Drug: NA-831 - 0.20 mg/kg
6 Subjects will take inhaled formulation of NA-831 once a day for 5 days
Drug: Drug: NA-831 - 0.20 mg/kg
NA-831 in nanoparticle inhalation formulation
Other Name: NA-81 is a neuroprotective drug

Placebo Comparator: Comparable Placebo- 0.20 mg/kg
3 subjects will take inhaled formulation of placebo once a day for 5 days
Drug: Placebo- 0.20 mg/kg
Placebo in nanoparticle inhalation formulation
Other Name: Placebo Comparator

Experimental: Drug: GS-5734 - 1.00 mg/kg
3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
Drug: Drug: GS-5734 - 1.00 mg/kg
GS-5734 in nanoparticle inhaled formulation
Other Name: GS-5734 (Remdesivir) is an antiviral drug

Placebo Comparator: Comparable Placebo- 1.00 mg.kg
3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
Drug: Placebo- 1.00 mg/kg
Placebo in nanoparticle inhalation formulation
Other Name: Placebo Comparator

Experimental: Drug: GS-5734 - 2.00 mg/kg
6 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
Drug: Drug: GS-5734 - 2.00 mg/kg
GS-5734 in nanoparticle inhaled formulation
Other Name: GS-5734 (Remdesivir) is an anti-viral drug

Placebo Comparator: Comparable Placebo - 2.00 mg/kg
3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days
Drug: Placebo- 2.00 mg/kg
Placebo in nanoparticle inhaled formulation
Other Name: Placebo Comparator

Experimental: Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)
3 Subjects- will take inhaled formulation NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) once/day for 5 days
Combination Product: Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)
The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
Other Name: Combination therapy of NA-831 a neuroprotective drug and GS-5734 an antiviral drug

Placebo Comparator: Placebo- 0.10- mg/kg placebo+1.00 mg mg/kg
3 Subjects - inhaled formulation of placebo once/day for 5 days
Combination Product: Placebo 0.10 mg + 1.00 mg/kg
The combined placebo are in nanoparticle inhaled formulation
Other Name: Placebo Comparator

Experimental: Drugs: NA-831( 0.20 mg/kg) + GS-5734 (2.00 mg/kg)
6 Subjects- inhaled formulation of NA-831 (0.20 mg/kg) + GS-5734 (2.00 mg/kg) once/day for 5 days
Combination Product: Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)
The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation
Other Name: Combination therapy of NA-831, a neuroprotective drug and GS-5734, an antiviral drug

Placebo Comparator: Placebo- 0.20 mg/kg + 2.00mg/kg
3 Subjects- inhaled formulation of placebo once/day for 5 days
Combination Product: Placebo 0.20 mg + 2.00 mg/kg
Placebo 0.10 mg + 1.00 mg/kg
Other Name: Placebo Comparator




Primary Outcome Measures :
  1. Proportion of Participants Experiencing any Treatment-Emergent Adverse Events [ Time Frame: First dose date up to Day 30 Follow-up Assessment ]
    AEs will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) V5.0

  2. Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities [ Time Frame: First dose date up to Day 30 Follow-up Assessment ]
    This will be assessed at various time points by clinical laboratory tests and vital signs.


Secondary Outcome Measures :
  1. Maximum Concentration (Cmax) - Pharmacokinetic Assessment [ Time Frame: 7 days ]
    Monitoring of the levels of drugs in subject sera at various time points to elucidate the maximum concentration (Cmax) of NA-831 and GS-5734 in human serum.

  2. Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment [ Time Frame: 7 days ]
    Monitoring of the levels of drugs in subject sera at various time points to elucidate the time to maximum concentration (Tmax) of NA-831 and GS-5734 in human serum

  3. AUC calculated from time of administration to the last measurable concentration (AUC0-last) - Pharmacokinetic Assessment [ Time Frame: 7 days ]
    Monitoring of the levels of drugs in subject sera at various time points to elucidate the area under the curve from time of administration to the last measurable of NA-831 and GS-5734

  4. Area Under the Curve Extrapolated to Infinity (AUC0-∞) [ Time Frame: 7 days ]
    Monitoring of the levels of drugs in subject sera at various time points to elucidate the area under the curve extrapolated to infinity (AUC0-∞) of NA-831 and GS-5734

  5. Half-Life (t1/2) - Pharmacokinetic Assessment [ Time Frame: 7 days ]
    Monitoring of the levels of drugs in subject sera at various time points to elucidate the half-life (t1/2) of NA-831 and GS-5734 in human serum.

  6. Volume of Distribution (Vd) - Pharmacokinetic Assessment [ Time Frame: 7 days ]
    Monitoring of the levels of drugs in subject sera through various time points to elucidate the volume of distribution (Vd) of NA-831 and GS-5734 in human serum.

  7. Clearance [CL] - Pharmacokinetic Assessment [ Time Frame: 7 days ]
    Monitoring of the levels of drugs in subject sera through at various time points to elucidate clearance [CL] of NA-831 and GS-5734 in human serum.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

  1. Healthy adult volunteers, aged 21 to 50 years old, men or women.
  2. Subjects negative for human immunodeficiency virus (HIV antibody screen), Hepatitis B virus surface Antigen (HBsAg) and Hepatitis C virus (HCV antibody screen).
  3. Subjects who are willing to comply with the requirements of the study protocol, attend scheduled visits and make themselves available for the duration of the study with access to a consistent means of telephone contact.
  4. Subjects who give written informed consent approved by the Internal Review Board governing the site.
  5. Satisfactory baseline medical assessment as assessed by physical examination and a stable health status. Normal laboratory values must be within normal range of the assessing site or show minor variations that are deemed not clinically significant as judged by the Investigator and acceptable for study entry.
  6. Accessible vein in the forearm for blood collection.
  7. Female subjects of childbearing potential may be enrolled in the study if they have negative urine pregnancy tests on the day of screening and day of admission.
  8. Female subjects of non-childbearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause.
  9. Both male (if he has a partner of childbearing potential) and female subjects (of childbearing potential) must agree to use adequate and reliable contraceptive measures (e.g. spermicides, condoms, contraceptive pills, etc.) or practice abstinence throughout the duration of the study (up to 30 days post-dosing).

EXCLUSION CRITERIA:

  1. Subject previously diagnosed with COVID-19 or had been issued with a quarantine order by the Center of Disease Control (CDC).
  2. Presence of acute infection in the preceding 14 days, or presence of a temperature ≥ 100.0 ˚F (oral or tympanic temperature assessment), or acute symptoms of any severity on the scheduled date of admission.
  3. History of severe drug and / or food allergies and / or known allergies to the trial product or its components.
  4. Female subject who is pregnant or breast-feeding.
  5. History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, , or immunosuppressive disorders.
  6. Any neurological disease or history of significant neurological disorder (e.g. meningitis, seizures, multiple sclerosis, vasculitis, migraines, Guillain-Barré syndrome [genetic/congenital or acquired]).
  7. Evidence of clinically significant anemia (HB < 10 g/dL) or any other significant active hematological disease, or having donated > 450 mL of blood within the past three (3) months.
  8. Participation or planned participation in a study involving the administration of an investigational compound within the past four (4) months or during this study period.
  9. Receipt of immunoglobulins and/or any blood products within nine (9) months of study enrolment or planned administration of any of these products during the study period.
  10. Evidence of Hepatitis B or C or HIV by laboratory testing.
  11. A positive test result for drugs of abuse (except a positive test result associated with prescription medication that has been reviewed and approved by the investigator) or alcohol at screening.
  12. Administration of any licensed vaccine within 30 days before the first study vaccine dose.
  13. Both male (if he has a partner of childbearing potential) and female subjects (of childbearing potential) who are unwilling to use adequate contraception or practice abstinence throughout the duration of the study (up to 84 days post-dosing).
  14. Any condition that, in the opinion of the Investigator, would complicate or compromise the study or well-being of the subject.

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04480333


Contacts
Layout table for location contacts
Contact: Brian Tran, MD 1-415-941-3133 BTran@neuroactiva.com
Contact: Markku Kurkinen, PhD 1-415-941-3133 MKurkinen@neuroactiva.com

Locations
Layout table for location information
United States, California
Coronavirus Research Institute Recruiting
Sunnyvale, California, United States, 94086
Contact: David Nguyen, MD       research@covri.org   
Contact: Lloyd Tran, PhD       LTran@neuroactiva.com   
Sub-Investigator: Markku Kurkinen, PhD         
Sponsors and Collaborators
NeuroActiva, Inc.
Investigators
Layout table for investigator information
Study Director: Lloyd Tran, PhD NeuroActiva, Inc.
Layout table for additonal information
Responsible Party: NeuroActiva, Inc.
ClinicalTrials.gov Identifier: NCT04480333    
Other Study ID Numbers: NEUROSIVIR
First Posted: July 21, 2020    Key Record Dates
Last Update Posted: July 21, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: We plan to share the Study Protocol
Supporting Materials: Study Protocol
Time Frame: 90 days after the completion of the study
Access Criteria: to be determined

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by NeuroActiva, Inc.:
Covid-19
Corona Virus Infection
Severe Acute Respiratory Syndrome
Severe Acute Respiratory Infection
Severe Acute Respiratory Syndrome (SARS) Pneumonia
Severe Acute Respiratory Syndrome of Upper Respiratory Tract
Neurodegeneration
Neuroinflammation
Cognitive decline
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Respiratory Tract Infections
Virus Diseases
Severe Acute Respiratory Syndrome
Coronavirus Infections
Pneumonia
Syndrome
Nerve Degeneration
Disease
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Antiviral Agents
Neuroprotective Agents
Anti-Infective Agents
Protective Agents
Physiological Effects of Drugs